GovTrack’s Bill Summary
We don’t have a summary available yet.
H.R. 733 (112th): Recalcitrant Cancer Research Act of 2012
- Introduced:
- Feb 16, 2011 (112th Congress, 2011–2013)
- Sponsor:
- Rep. Anna Eshoo [D-CA14]
- Status:
- Died (Passed House)
The bill’s title was written by the bill’s sponsor. H.R. stands for House of Representatives bill.
- Full Title
To provide for scientific frameworks with respect to recalcitrant cancers.
- Summary
-
No summaries available.
- Text
-
Last updated Sep 20, 2012.
9 pages
- Primary Source
-
View on THOMAS (The Library of Congress)
GovTrack gets most information from THOMAS, which is updated generally one day after events occur. Activity since the last update may not be reflected here.
- Citation
-
Click a format for a citation suggestion:
Library of Congress Summary
The summary below was written by the Congressional Research Service, which is a nonpartisan division of the Library of Congress.
9/19/2012--Passed House amended.
Recalcitrant Cancer Research Act of 2012 - Amends the Public Health Service Act to require the Director of the National Cancer Institute (NCI) to develop a scientific framework for research on recalcitrant cancers (cancer with a 5-year relative survival rate below 50%), which includes:
(1) a review of the status of research, such as a summary of findings, identification of promising scientific advances, a description of the availability of qualified scientific researchers, and the identification of resources available to facilitate research;
(2) identification of research questions that have not been adequately addressed; and
(3) recommendations for actions to advance research and for appropriate benchmarks to measure progress on achieving such actions.
Requires the Director to develop the framework within 18 months and review and update it every 5 years.
Requires the Director to identify within 6 months 2 or more recalcitrant cancers that have a 5-year relative survival rate of less than 20%, and are estimated to cause the death of at least 30,000 individuals in the United States per year.
Authorizes the Director to identify additional such cancers and to consider additional metrics of progress (such as incidence and mortality rates) against such cancer.
Requires the Director to convene a working group for each identified cancer to provide expertise on, and assist in developing, a scientific framework under this Act. Requires the Director to consider each relevant scientific framework developed under this Act when making recommendations for exception funding for grant applications.
House Republican Conference Summary
The summary below was written by the House Republican Conference, which is the caucus of Republicans in the House of Representatives.
This summary can be found at http://www.gop.gov/bill/112/2/hr733.
Background
According to the Subcommittee, recalcitrant cancers, like those that develop in the pancreas, liver, and ovaries, hide in tissue and are difficult to detect. With their unique molecular structure, these cancers spread under the radar of traditional diagnostic tools. When they are eventually diagnosed, the damage is substantial, the treatments are ineffective, and the prognosis is poor. This bill originally focused solely on pancreatic cancer. A substitute amendment, adopted by voice vote, expanded the focus to all recalcitrant cancers.
Summary
The Recalcitrant Cancer Research Act of 2012 would amend the Public Health Service Act to direct the National Cancer Institute to establish a scientific framework that will guide research efforts on recalcitrant cancers. Within 6 months of enactment, the Director of the National Cancer Institute (NCI) would be required to identify two or more cancers that meet the established criteria—a 5-year survival rate of less than 20 percent and a death rate of at least 30,000. For each initial cancer identified, the Director will convene a working group that will develop the scientific framework not later than 18 months after the date of enactment. In addition, the scientific framework will be reviewed and updated within 5 years of its development. The Director may at any time identify other recalcitrant cancers, defined as cancers with survival rates of below 50 percent, in which to conduct a scientific framework.
Cost
There was no Congressional Budget Office (CBO) cost estimate available for this bill.
House Democratic Caucus Summary
The House Democratic Caucus does not provide summaries of bills.
So, yes, we display the House Republican Conference’s summaries when available even if we do not have a Democratic summary available. That’s because we feel it is better to give you as much information as possible, even if we cannot provide every viewpoint.
We’ll be looking for a source of summaries from the other side in the meanwhile.
The bill contains the following citations to other parts of U.S. law:
United States Code
The United States Code is the compilation of permanent laws enacted by Congress. Temporary and other non-permanent laws do not appear in the United States Code. (About half of the United States Code is the law itself, called positive law. The other half is merely a compilation of the laws but has no legal significance.)
- Title 42: THE PUBLIC HEALTH AND WELFARE
- Chapter 6A: PUBLIC HEALTH SERVICE
- Subchapter III: NATIONAL RESEARCH INSTITUTES
- Part C: Specific Provisions Respecting National Research Institutes
- Subpart 1: national cancer institute
- Section 285: Purpose of Institute